Iterum Therapeutics PLC (ITRM) - Net Assets
Based on the latest financial reports, Iterum Therapeutics PLC (ITRM) has net assets worth $-7.38 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.50 Million) and total liabilities ($39.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ITRM asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.38 Million |
| % of Total Assets | -22.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 93.23 |
Iterum Therapeutics PLC - Net Assets Trend (2016–2024)
This chart illustrates how Iterum Therapeutics PLC's net assets have evolved over time, based on quarterly financial data. Also explore ITRM total assets for the complete picture of this company's asset base.
Annual Net Assets for Iterum Therapeutics PLC (2016–2024)
The table below shows the annual net assets of Iterum Therapeutics PLC from 2016 to 2024. For live valuation and market cap data, see Iterum Therapeutics PLC (ITRM) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-4.08 Million | +36.26% |
| 2023-12-31 | $-6.40 Million | -122.87% |
| 2022-12-31 | $28.00 Million | -44.26% |
| 2021-12-31 | $50.23 Million | +199.36% |
| 2020-12-31 | $-50.56 Million | -92.69% |
| 2019-12-31 | $-26.24 Million | -136.63% |
| 2018-12-31 | $71.62 Million | +81.35% |
| 2017-12-31 | $39.49 Million | +74.23% |
| 2016-12-31 | $22.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Iterum Therapeutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46074100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $315.00K | % |
| Other Components | $481.68 Million | % |
| Total Equity | $-4.08 Million | 100.00% |
Iterum Therapeutics PLC Competitors by Market Cap
The table below lists competitors of Iterum Therapeutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nextferm Technologies Ltd
TA:NXFR
|
$2.09 Million |
|
AFC Energy plc
LSE:AFC
|
$2.10 Million |
|
Propanc Biopharma, Inc. Common Stock
NASDAQ:PPCB
|
$2.10 Million |
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
$2.10 Million |
|
Constellation Technologies Ltd
AU:CT1
|
$2.09 Million |
|
Signing Day Sports, Inc.
NYSE MKT:SGN
|
$2.08 Million |
|
Korab Resources Ltd
AU:KOR
|
$2.08 Million |
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
$2.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Iterum Therapeutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -6,403,000 to -4,081,000, a change of 2,322,000.
- Net loss of 24,774,000 reduced equity.
- New share issuances of 26,691,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 406,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.77 Million | -607.06% |
| Share Issuances | $26.69 Million | +654.03% |
| Other Comprehensive Income | $-1.00K | -0.02% |
| Other Changes | $406.00K | +9.95% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Iterum Therapeutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $1.62 | $0.04 | x |
| 2017-12-31 | $71.92 | $0.04 | x |
| 2018-12-31 | $123.00 | $0.04 | x |
| 2019-12-31 | $-1.81 | $0.04 | x |
| 2020-12-31 | $-2.11 | $0.04 | x |
| 2021-12-31 | $4.61 | $0.04 | x |
| 2022-12-31 | $2.29 | $0.04 | x |
| 2023-12-31 | $-0.49 | $0.04 | x |
| 2024-12-31 | $-0.21 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Iterum Therapeutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-64.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -59.40% | 0.00% | 0.00x | 1.19x | $-15.73 Million |
| 2017 | -74.46% | -5788.58% | 0.01x | 1.18x | $-33.36 Million |
| 2018 | -107.59% | -8867.20% | 0.01x | 1.37x | $-84.22 Million |
| 2019 | 0.00% | -278729.73% | 0.00x | 0.00x | $-100.51 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.95 Million |
| 2021 | -182.27% | 0.00% | 0.00x | 1.82x | $-96.59 Million |
| 2022 | -158.70% | 0.00% | 0.00x | 2.39x | $-47.23 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.73 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.37 Million |
Industry Comparison
This section compares Iterum Therapeutics PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Iterum Therapeutics PLC (ITRM) | $-7.38 Million | -59.40% | N/A | $2.09 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more